Integrated Filing — IndAS



General information about company

Scrip Code 506820
NSE Symbol ASTRAZEN
MSEI Symbol NA
ISIN INE203A01020
Name of company ASTRAZENECA PHARMA INDIA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 05-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 30-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Healthcare
Start date and time of board meeting 05-11-2026   13:30:00
End date and time of board meeting 05-11-2026   15:50:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 11-02-2025
Indicate Company website link for updated RPT policy of the Company https://www.astrazeneca.in/content/dam/az-in/pdf/2025/investor_relations_section_DU/Policy%20on%20Related%20Party%20Transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
1-The Statements of financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the “Act”) [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2-The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided. 3-Exceptional items: a-Exceptional items for the quarter ended 30 September 2026 , 30 June 2026 and 30 September 2025 and year ended 31 March 2026 consists of expenses related to closure of the manufacturing site. (Refer note 4 below) b-The exceptional items for the quarter and half year ended 30 September 2026 consists of BBMP interest (Refer note 5 below) 4-During an earlier year, the Company had made an announcement to Stock exchanges about its intention to exit the Company’s manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. During the quarter ended 30 June 2025, the operations at the manufacturing site have ceased and the Company is now in the process of sale of assets related to the manufacturing site. The cost, [(charge)/ reversal] related to closure of manufacturing site included in exceptional item is Rs. 6.5, Rs. (2.4), Rs. (52.9), Rs. 4.1, Rs. (56.5) and Rs. (52.5) for the quarter ended September 30, 2026, June 30, 2026, September 30, 2025, for the half year ended September 30, 2026, September 30, 2025 and full year March 31, 2026 respectively. The disclosure for the defalult of loans and denbt securities is not applicable to the Company.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 72,910.00 1,41,189.00
Other income 1,512.00 2,435.00
Total income 74,422.00 1,43,624.00
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 62,410.00 92,872.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (15,025.00) (766.00)
(d) Employee benefit expense 6,785.00 14,701.00
(e) Finance costs 189.00 384.00
(f) Depreciation, depletion and amortisation expense 535.00 1,058.00
(f) Other Expenses
1 Selling, marketing and distribution expense 1,770.00 4,845.00
2 Other Expenses 7,413.00 15,086.00
Total other expenses 9,183.00 19,931.00
Total expenses 64,077.00 1,28,180.00
3 Total profit before exceptional items and tax 10,345.00 15,444.00
4 Exceptional items (1,496.00) (1,520.00)
5 Total profit before tax 8,849.00 13,924.00
6 Tax expense
7 Current tax 2,503.00 3,590.00
8 Deferred tax 113.00 308.00
9 Total tax expenses 2,616.00 3,898.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 6,233.00 10,026.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 6,233.00 10,026.00
17 Other comprehensive income net of taxes (28.00) (58.00)
18 Total Comprehensive Income for the period 6,205.00 9,968.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 500.00 500.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 24.93 40.1
Diluted earnings (loss) per share from continuing operations 0 0
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 24.93 40.1
Diluted earnings (loss) per share from continuing and discontinued operations 0 0
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 5-The Company had received a notice from Bruhat Bangalore Mahanagara Palike (BBMP) on 7 August 2014, followed by reminder notices, demanding Rs. 70.8 (2026: Rs. 70.8) as improvement charges for its factory land and had recorded a provision against this demand in the earlier years. Following the final judgement of the High Court of Karnataka holding that the property falls within the jurisdictional limits, the Company intends to settle the matter. During the current period, based on the Company’s assessment and information available to date , a provision of Rs. 156.1 towards interest relating to the aforesaid improvement charges has been recognised and has been presented as an exceptional item. The provision represents the Company’s current estimate of probable outflow and will be reassessed based on the ultimate determination/ outcome of the matter. 6-During the current year , the Company received an order from National Pharmaceutical Pricing Authority to deposit an amount of Rs.1,486.58 (including interest thereon) alleging overcharging of a combination respiratory drug sold during the period between May 2016 to November 2025. Subsequent to the quarter end, the Company received a reminder notice on 05 October 2026 for Rs. 1,511.96, including interest calculated till 30 October 2026. Pursuant to the writ petition filed by the company, the Hon'ble High Court vide its order dated 29 October 2026 has directed that no coercive steps be taken by NPPA in respect of collection of the amount demanded till the next date of hearing i.e. listed on 11 January, 2027. Based on assessment, supported by external legal advice, Management has concluded that it has reasonable grounds to defend its position. Accordingly, no provision has been made in these financial statements. 7-This Statement of unaudited financial results were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 05 November 2026. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 9,905.00
Capital work-in-progress 1,559.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 0.00
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 0.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Security deposits 732.00
2 Other term deposits 405.00
Total of other non-current financial assets 1,137.00
Total non-current financial assets 1,137.00
Deferred tax assets (net) 3,493.00
Other non-current assets
1 Balance with government authorities 142.00
2 Current tax assets 8,881.00
Total of other non-current assets 9,023.00
Total non-current assets 25,117.00
2 Current assets
Inventories 1,03,500.00
Current financial asset
Current investments 0.00
Trade receivables, current 28,500.00
Cash and cash equivalents 57,381.00
Bank balance other than cash and cash equivalents 133.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 1,144.00
Total current financial assets 87,158.00
Current tax assets (net) 0.00
Other current assets
1 Balances with Government Authorities 2,275.00
2 Advances to suppliers 28.00
3 Prepaid expenses 571.00
4 Employee advances 130.00
Total of other current assets 3,004.00
Total current assets 1,93,662.00
3 Non-current assets classified as held for sale 361.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 2,19,140.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 500.00
Other equity 87,392.00
Total equity attributable to owners of parent 87,892.00
Non controlling interest
Total equity 87,892.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 8,393.00
Total of other non-current financial liabilities 8,393.00
Total non-current financial liabilities 8,393.00
Provisions, non-current 2,038.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Deferred revenue 1,866.00
Total of other non-current liabilities 1,866.00
Total non-current liabilities 12,297.00
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 345.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 97,229.00
Total Trade payable 97,574.00
Other current financial liabilities
1 Lease liabilities 1,228.00
2 Payable to employees 2,032.00
3 Unclaimed dividend 133.00
4 Other payables 511.00
Total of other current financial liabilities 3,904.00
Total current financial liabilities 1,01,478.00
Other current liabilities 11,891.00
1 Statutory liabilities 1,541.00
2 Refund liabilities for expected sales returns 582.00
3 Deferred revenue 7,274.00
4 Advance from customers 224.00
5 Others 2,270.00
Total of other current liabilities 11,891.00
Provisions, current 5,041.00
Current tax liabilities (Net) 541.00
Deferred government grants, Current 0.00
Total current liabilities 1,18,951.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 1,31,248.00
Total equity and liabilites 2,19,140.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement (losses)/ gains on post employment benefit obligations (37.00) (77.00)
Total Amount of items that will not be reclassified to profit and loss (37.00) (77.00)
2 Income tax relating to items that will not be reclassified to profit or loss (9.00) (19.00)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income (28.00) (58.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 13,924.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 384.00
Adjustments for decrease (increase) in inventories (767.00)
Adjustments for decrease (increase) in trade receivables, current (8,021.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 394.00
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (26.00)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 19,304.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 2,236.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,058.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 32.00
Adjustments for provisions, current (132.00)
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 21.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (11.00)
Adjustments for dividend income 0.00
Adjustments for interest income 1,090.00
Adjustments for share-based payments (7.00)
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 518.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 13,893.00
Net cash flows from (used in) operations 27,817.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 4,579.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 23,238.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 1,559.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 1,007.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (552.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 693.00
Dividends paid 9,000.00
Interest paid 384.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (10,077.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 12,609.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 12,609.00
Cash and cash equivalents cash flow statement at beginning of period 44,772.00
Cash and cash equivalents cash flow statement at end of period 57,381.00





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 AstraZeneca Pharma India Limited AstraZeneca UK Limited, United Kingdom Step up Holding Company Purchase of goods or services 2,31,795.60 NA 57,825.00 25,069.00 45,718.00
2 AstraZeneca Pharma India Limited AstraZeneca AB, Sweden Step up Holding Company Sale of goods or services 19,800.00 NA 7,931.00 2,349.00 3,862.00
3 AstraZeneca Pharma India Limited AstraZeneca AB, Sweden Step up Holding Company Purchase of goods or services 1,30,200.10 NA 32,461.00 35,915.00 32,563.00
4 AstraZeneca Pharma India Limited AstraZeneca UK Limited, United Kingdom Step up Holding Company Any other transaction Recovery pursuant to Advance Pricing Agreement 0.00 NA 0.00 49.00 0.00
5 AstraZeneca Pharma India Limited AstraZeneca AB, Sweden Step up Holding Company Any other transaction Recovery pursuant to Advance Pricing Agreement 0.00 NA 0.00 60.00 0.00
6 AstraZeneca Pharma India Limited AstraZeneca UK Limited, United Kingdom Step up Holding Company Any other transaction Recovery of reimbursable expenses 6,000.00 NA 337.00 306.00 271.00
7 AstraZeneca Pharma India Limited AstraZeneca Singapore Pte Ltd, Singapore Fellow subsidiary Any other transaction Recovery of reimbursable expenses 600.00 NA 166.00 21.00 101.00
8 AstraZeneca Pharma India Limited AstraZeneca Pharmaceuticals (Pty) Limited, South Africa Fellow subsidiary Any other transaction Recovery of reimbursable expenses 600.00 NA 0.00 25.00 0.00
9 AstraZeneca Pharma India Limited AstraZeneca UK Limited, United Kingdom Step up Holding Company Any other transaction Employee Share Compensation expenses 2,200.00 NA 344.00 0.00 145.00
10 AstraZeneca Pharma India Limited P.T. AstraZeneca Indonesia Fellow subsidiary Any other transaction Recovery of reimbursable expenses 800.00 NA 127.00 24.00 99.00
11 AstraZeneca Pharma India Limited AstraZeneca Pharmaceuticals Limited, Kenya Fellow subsidiary Any other transaction Recovery of reimbursable expenses 400.00 NA 83.00 38.00 26.00
12 AstraZeneca Pharma India Limited AstraZeneca Pharmaceuticals LP US Fellow subsidiary Any other transaction Recovery of reimbursable expenses 1,000.00 NA 186.00 118.00 186.00
13 AstraZeneca Pharma India Limited AstraZeneca Vietnam Fellow subsidiary Any other transaction Recovery of reimbursable expenses 0.00 NA 0.00 45.00 45.00
14 AstraZeneca Pharma India Limited AstraZeneca AB, Sweden Fellow subsidiary Any other transaction Recovery of reimbursable expenses 0.00 NA 0.00 1.00 0.00
15 AstraZeneca Pharma India Limited AstraZeneca Pharmaceuticals AB, Sweden Holding Company Any other transaction Dividend Paid NA 6,750.00 0.00 0.00 Textual Information(1)
16 AstraZeneca Pharma India Limited AstraZeneca Pharma India Limited Management Staff Provident Fund Trust Employees' Benefit Plan Any other transaction Contribution to Trust NA 462.90 0.00 0.00 Textual Information(2)
17 AstraZeneca Pharma India Limited AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust Employees' Benefit Plan Any other transaction Contribution to Trust NA 29.70 0.00 0.00 Textual Information(3)
18 AstraZeneca Pharma India Limited Mr.Praveen Akkinepally Managing Director Any other transaction Short term Employee Benefits NA 195.00 0.00 0.00 Textual Information(4)
19 AstraZeneca Pharma India Limited Mr.Praveen Akkinepally Managing Director Any other transaction Long term Employee Benefits NA 17.10 0.00 0.00 Textual Information(5)
20 AstraZeneca Pharma India Limited Mr.Praveen Akkinepally Managing Director Any other transaction Post Employment Benefit NA 10.40 0.00 0.00 Textual Information(6)
21 AstraZeneca Pharma India Limited Mr.Praveen Akkinepally Managing Director Any other transaction Employee Share Compensation Expenses NA 14.70 0.00 0.00 Textual Information(7)
22 AstraZeneca Pharma India Limited Ms. Bhavana Agarwal Director and Chief Financial Officer Any other transaction Short term Employee Benefits NA 95.50 0.00 0.00 Textual Information(8)
23 AstraZeneca Pharma India Limited Ms. Bhavana Agarwal Director and Chief Financial Officer Any other transaction Long term Employee Benefits NA 4.00 0.00 0.00 Textual Information(9)
24 AstraZeneca Pharma India Limited Ms. Bhavana Agarwal Director and Chief Financial Officer Any other transaction Post Employment Benefit NA 1.10 0.00 0.00 Textual Information(10)
25 AstraZeneca Pharma India Limited Ms. Bhavana Agarwal Director and Chief Financial Officer Any other transaction Employee Share Compensation Expenses NA (17.50) 0.00 0.00 Textual Information(11)
26 AstraZeneca Pharma India Limited Ms. Tanya Sanish Company Secretary Any other transaction Short term Employee Benefits NA 30.50 0.00 0.00 Textual Information(12)
27 AstraZeneca Pharma India Limited Ms. Tanya Sanish Company Secretary Any other transaction Long term Employee Benefits NA 1.40 0.00 0.00 Textual Information(13)
28 AstraZeneca Pharma India Limited Ms. Tanya Sanish Company Secretary Any other transaction Post Employment Benefit NA 2.30 0.00 0.00 Textual Information(14)
29 AstraZeneca Pharma India Limited Ms. Revathy Ashok Independent Director Any other transaction Sitting fees paid to independent directors NA 7.00 0.00 0.00
30 AstraZeneca Pharma India Limited Ms. Shilpa Divekar Nirula Independent Director Any other transaction Sitting fees paid to independent directors NA 6.00 0.00 0.00
31 AstraZeneca Pharma India Limited Ms. Monica Widhani Independent Director Any other transaction Sitting fees paid to independent directors NA 7.00 0.00 0.00
32 AstraZeneca Pharma India Limited Ms. Monica Widhani Independent Director Any other transaction Dividend Paid NA 0.00 0.00 0.00
Total value of transaction during the reporting period 1,07,077.10



Text Block

Textual Information(1) Approved by shareholders
Textual Information(2) In line with stautory requirements
Textual Information(3) In line with stautory requirements
Textual Information(4) Approved by nomination and remuneration committee
Textual Information(5) Approved by nomination and remuneration committee
Textual Information(6) Approved by nomination and remuneration committee
Textual Information(7) Approved by nomination and remuneration committee
Textual Information(8) Approved by nomination and remuneration committee
Textual Information(9) Approved by nomination and remuneration committee
Textual Information(10) Approved by nomination and remuneration committee
Textual Information(11) Approved by nomination and remuneration committee
Textual Information(12) Approved by nomination and remuneration committee
Textual Information(13) Approved by nomination and remuneration committee
Textual Information(14) Approved by nomination and remuneration committee